Are LITS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies LITS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / LITS / insiders

NNVC (37) ALDX (39) EDSA (29) GRDX (39) ⌘ Pro Terminal →

Lite Strategy Inc. (LITS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.97 -13.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.94

Lite Strategy Inc. (LITS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $34.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LITS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LITS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lite Strategy Inc. (NASDAQ: LITS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.97 (-13.60% 1D, market cap $34.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LITS ranks #414 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LITS compare to NNVC and ALDX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LITS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, NNVC (NanoViricides Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $34.0M) and ALDX (Aldeyra Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $33.8M). Among the 5-stock peer group, LITS leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LITS?

▼

Per LITS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001262104), Lite Strategy Inc. generated $48.9M in revenue (-25.2% YoY), -$15.9M in net income, and -$20.8M in free cash flow against $82.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.94 (-2.64%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LITS)Realized 20D OHLCV Swing Band: ±12%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY LITS SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 11.68 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)

FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 44.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.21-1.7% Next Q

Q2 (-2Q)

Grade D$1.19-2.5% Next Q

Q3 (-1Q)

Grade D$1.16-16.4% Next Q

Current

Grade D-$0.97-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LITS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LITS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.18) and Max Pain ($1.02) forces dealer call-delta covering toward $2.37.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LITS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LITS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LITS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LITS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LITS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LITS)

✓Walkthrough of LITS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LITS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.91%▼ SUPPORT BREAKDOWN

2026-11-03O $1.17H $1.17L $0.97C $0.97VOL 270.5K

RES: $1.76SUP: $1.04SMA50: $1.18SMA200: $1.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LITS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LITS Butterfly Map → + Track LITS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -25.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LITS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LITS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LITS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LITS)

Health Care Rank #414 of 1015 ⚔️ NNVC vs LITS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LITS vs. NNVC, ALDX, EDSA, GRDX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lite Strategy Inc. (LITS) ranks #414 by composite RQD confidence (43/100, grade D-) and #784 by equity capitalization ($34.1M). Within this direct 5-issuer industry benchmark cohort, LITS leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LITS ACTIVE Lite Strategy Inc.	D-	43/100	—	—	-18.9%	-13.60%	$34.1M	Benchmark Subject
NNVC NanoViricides Inc.	D-	37/100	—	—	-35.0%	+1.50%	$34.0M	/nnvc-vs-lits →
ALDX Aldeyra Therapeutics Inc.	D-	39/100	—	—	-35.0%	+4.09%	$33.8M	/aldx-vs-lits →
EDSA Edesa Biotech Inc.	E	29/100	—	—	-35.0%	-5.06%	$34.7M	/edsa-vs-lits →
GRDX GridAI Technologies Corp.	D-	39/100	—	-30.0%	-20.0%	-3.43%	$35.4M	/grdx-vs-lits →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001262104 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lite Strategy Inc. (LITS) reported GAAP revenue of $48.9M (-25.2% vs. FY2024 revenue of $65.3M , and +0.1% cumulative change since FY2023) , GAAP net income of -$15.9M, operating cash flow of -$20.8M, and free cash flow of -$20.8M (+58.7% YoY). On the balance sheet, LITS closed FY2025 with $82.9M in total assets against $0 in total debt (Altman Z-Score: 11.68, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$48.9M	-$15.9M	-$20.8M	-$20.8M	$82.9M	—
FY2024 (FY)	2024-06-30	$65.3M	$18.0M	-$50.5M	-$50.5M	$24.4M	—
FY2023 (FY)	2023-06-30	$48.8M	-$32.0M	-$52.5M	-$52.5M	—	—

3. LITS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LITS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LITS compare to NNVC and ALDX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LITS?

Where is LITS trading relative to its 50-day, 200-day, and 52-week technical levels?

LITS last traded at $0.97 (-13.60% on volume of 729,818 shares), positioning the stock -17.80% below its 50-day simple moving average ($1.18) and -11.01% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.69 to $2.26, LITS sits at the 17.8% percentile with a 14-day RSI of 44.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $1.09).

Direct Sub-Reports: LITS RQD Cockpit LITS 12M Forecast LITS Earnings & Move LITS Dividends & DRIP LITS Insiders & 13F LITS Whale Options LITS Profit Sankey LITS News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LITS — Lite Strategy Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lite Strategy Inc. (LITS) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.97 (-13.60% 1D, market capitalization $34.1M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -18.9%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of 11.68, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (LITS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $65.3M for FY 2024 and — for FY 2025, indicating that reported revenue did not persist into the most recent fiscal year. — for how the company monetizes its activities.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Lite Strategy Inc. (LITS) reported $48.9M in annual revenue (up from $65.3M in FY2024, -25.2% YoY) and -$15.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($48.8M revenue, -$32.0M net income) through FY2025, LITS scaled operating cash flow to -$20.8M and free cash flow to -$20.8M, backed by $82.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.69 – $2.26 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the option grants at $1.19 sit close to the current $1.

Key Question #1: Can LITS sustain or expand its — operating margin and -18.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $48.9M and free cash flow of -$20.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is LITS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LITS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lite Strategy Inc. (LITS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LITS Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

Lite Strategy, Inc. Estimates – NASDAQ:LITS

TradingView report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A 100,000-option director grant at Lite Strategy (LITS) carries a $1.19 exercise price.

Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A director receives 100,000 options with a $1.19 exercise price at Lite Strategy (LITS).

Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH ad-hoc-news.de • 1d ago

Lite Strategy stock falls 4.88% in US session

ad-hoc-news.de report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

600,000 options awarded to Lite Strategy (LITS) CEO Justin J. File carry a $1.19 exercise price.

Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

An annual grant gives Lite Strategy (LITS) director James P. Flynn 100,000 options with a $1.19 exercise price.

Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 2d ago

LITS Q4 2024 Earnings: Loss Per Share Nearly Double Consensus Despite 4.2% Stock Gain - Strong Earnings Momentum

https://www.dars.gov.et/ report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

A 100,000-option annual grant at Lite Strategy (LITS) gives director Joshua Riezman 25% immediate vesting.

Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LITS Bull vs. Bear Conversation Board — What's Your Call at $0.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LITS 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.38 (+23.2%)

📌 Pinned Debate

Altman Z-Score of 11.68 indicates a balance sheet that scores strongly on the forensic pillar despite weak operations.

The street is overcomplicating Lite Strategy Inc. (LITS). Altman Z-Score of 11.68 indicates a balance sheet that scores strongly on the forensic pillar despite weak operations.. With an RQD score of 43/100 (D-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.21.

EarningsSniper 🐂 BULL

Both sides have a point here — LITS's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.87 (-22.3%)

Spot @ $1.12

ROIC of -18.9%, zero reported FY 2025 revenue, and a Piotroski F-Score of 1/9 point to a deteriorating cash engine.

I respect the product at Lite Strategy Inc., but the stock at $1.12 is a different story. ROIC of -18.9%, zero reported FY 2025 revenue, and a Piotroski F-Score of 1/9 point to a deteriorating cash engine.. FCF yield is 0.0% and RQD sits at 43/100 (D-) — why pay up here when you can wait for next quarter's numbers?